Prostate Cancer New Protocol: Niraparib and abiraterone acetate plus prednisone for BRCA-mutated metastatic castration-resistant prostate cancer Ulas D. Bayraktar, MD 2023-06-06
Biliary Tract Cancer New Protocol: Pembrolizumab with CISplatin and Gemcitabine in Metastatic Biliary Tract Cancer Ulas D. Bayraktar, MD 2023-05-20
Colorectal Cancer New Protocl: Trifluridine-Tipiracil and Bevacizumab in Metastatic Colorectal Cancer Ulas D. Bayraktar, MD 2023-05-20
Chronic Lymphocytic Leukemia New Reference: Ibrutinib and Rituximab for CLL Ulas D. Bayraktar, MD 2023-05-20
Follicular Lymphoma New Reference: SubQ Rituximab for Follicular Lymphoma Ulas D. Bayraktar, MD 2023-05-20
Breast Cancer New Reference: Trastuzumab Deruxtecan for her2-Positive Breast Cancer Ulas D. Bayraktar, MD 2023-05-20
Skin Cancer (Other than Melanoma) New Drug: Retifanlimab in Advanced Merkel Cell Carcinoma Ulas D. Bayraktar, MD 2023-05-20
Breast Cancer New Indication: Adjuvant Abemaciclib in HR+ Breast Cancer Ulas D. Bayraktar, MD 2023-05-20
Uterine Cancer New Protocol: Pembrolizumab with Chemotherapy in Advanced Endometrial Cancer Ulas D. Bayraktar, MD 2023-04-14
Bladder Cancer New Protocol: Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Cancer Ulas D. Bayraktar, MD 2023-04-14
